{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:38:25Z","timestamp":1768549105408,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"the Ministry of Health & Welfare, Republic of Korea","award":["a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)(grant number: HI16C0061)"],"award-info":[{"award-number":["a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)(grant number: HI16C0061)"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13075-017-1482-y","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T13:29:11Z","timestamp":1513344551000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs"],"prefix":"10.1186","volume":"19","author":[{"given":"Soo-Kyung","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiyoung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minkyung","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon-Kyoung","family":"Sung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"issue":"6","key":"1482_CR1","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.semarthrit.2007.08.006","volume":"37","author":"L Abasolo","year":"2008","unstructured":"Abasolo L, Judez E, Descalzo MA, Gonzalez-Alvaro I, Jover JA, Carmona L, et al. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum. 2008;37(6):388\u201397.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1482_CR2","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/art.30134","volume":"63","author":"YJ Chen","year":"2011","unstructured":"Chen YJ, Chang YT, Wang CB, Wu CY. The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan. Arthritis Rheum. 2011;63(2):352\u20138.","journal-title":"Arthritis Rheum"},{"key":"1482_CR3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","volume":"17","author":"TA Simon","year":"2015","unstructured":"Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"1482_CR4","first-page":"217","volume":"16","author":"E Shacter","year":"2002","unstructured":"Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park). 2002;16(2):217\u201326. 29; discussion 30\u20132.","journal-title":"Oncology (Williston Park)"},{"issue":"6","key":"1482_CR5","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0049-0172(97)80023-6","volume":"26","author":"L Georgescu","year":"1997","unstructured":"Georgescu L, Quinn GC, Schwartzman S, Paget SA. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum. 1997;26(6):794\u2013804.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"1482_CR6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","volume":"42","author":"A Hashimoto","year":"2015","unstructured":"Hashimoto A, Chiba N, Tsuno H, Komiya A, Furukawa H, Matsui T, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42(4):564\u201371.","journal-title":"J Rheumatol"},{"issue":"8","key":"1482_CR7","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","volume":"52","author":"JM Kremer","year":"2005","unstructured":"Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(8):2263\u201371.","journal-title":"Arthritis Rheum"},{"issue":"22","key":"1482_CR8","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343(22):1594\u2013602.","journal-title":"N Engl J Med"},{"issue":"9602","key":"1482_CR9","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861\u201374.","journal-title":"Lancet"},{"issue":"3","key":"1482_CR10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10555-006-9005-3","volume":"25","author":"F Balkwill","year":"2006","unstructured":"Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006;25(3):409\u201316.","journal-title":"Cancer Metastasis Rev"},{"issue":"19","key":"1482_CR11","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"T Bongartz","year":"2006","unstructured":"Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275\u201385.","journal-title":"JAMA"},{"issue":"7","key":"1482_CR12","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/ard.2008.094904","volume":"68","author":"T Bongartz","year":"2009","unstructured":"Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann Rheum Dis. 2009;68(7):1177\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1482_CR13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","volume":"20","author":"J Askling","year":"2011","unstructured":"Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf. 2011;20(2):119\u201330.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"1482_CR14","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/ard.2008.091025","volume":"68","author":"JP Leombruno","year":"2009","unstructured":"Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68(7):1136\u201345.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1482_CR15","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","volume":"63","author":"AE Thompson","year":"2011","unstructured":"Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2011;63(6):1479\u201385.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"1482_CR16","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/ard.2008.097527","volume":"68","author":"TA Simon","year":"2009","unstructured":"Simon TA, Smitten AL, Franklin J, Askling J, Lacaille D, Wolfe F, et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis. 2009;68(12):1819\u201326.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1482_CR17","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","volume":"13","author":"MH Schiff","year":"2011","unstructured":"Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13(5):R141.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"1482_CR18","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/2012.jama.10857","volume":"308","author":"MA Lopez-Olivo","year":"2012","unstructured":"Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, Pollono EN, Cueto JP, Gonzales-Crespo MR, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA. 2012;308(9):898\u2013908.","journal-title":"JAMA"},{"issue":"8","key":"1482_CR19","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3899\/jrheum.141210","volume":"42","author":"K Yamamoto","year":"2015","unstructured":"Yamamoto K, Goto H, Hirao K, Nakajima A, Origasa H, Tanaka K, et al. Longterm safety of tocilizumab: results from 3\u00a0years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol. 2015;42(8):1368\u201375.","journal-title":"J Rheumatol"},{"issue":"6","key":"1482_CR20","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","volume":"74","author":"LK Mercer","year":"2015","unstructured":"Mercer LK, Lunt M, Low AL, Dixon WG, Watson KD, Symmons DP, et al. Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2015;74(6):1087\u201393.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1482_CR21","doi-asserted-by":"crossref","first-page":"e6055","DOI":"10.1097\/MD.0000000000006055","volume":"96","author":"JL Lan","year":"2017","unstructured":"Lan JL, Tseng CH, Chen JH, Cheng CF, Liang WM, Tsay GJ. Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-alpha inhibitor. Medicine (Baltimore). 2017;96(7):e6055.","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"1482_CR22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13075-014-0449-5","volume":"16","author":"CY Wu","year":"2014","unstructured":"Wu CY, Chen DY, Shen JL, Ho HJ, Chen CC, Kuo KN, et al. The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study. Arthritis Res Ther. 2014;16(5):449.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"1482_CR23","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3899\/jrheum.100995","volume":"38","author":"EC Keystone","year":"2011","unstructured":"Keystone EC. Does anti-tumor necrosis factor-alpha therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol. 2011;38(8):1552\u201362.","journal-title":"J Rheumatol"},{"issue":"3","key":"1482_CR24","first-page":"206","volume":"52","author":"YJ Song","year":"2009","unstructured":"Song YJ. The South Korean Health Care System. Japan Med Assoc J. 2009;52(3):206\u20139.","journal-title":"Japan Med Assoc J"},{"issue":"12","key":"1482_CR25","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s00296-013-2833-x","volume":"33","author":"SK Cho","year":"2013","unstructured":"Cho SK, Sung YK, Choi CB, Kwon JM, Lee EK, Bae SC. Development of an algorithm for identifying rheumatoid arthritis in the Korean National Health Insurance claims database. Rheumatol Int. 2013;33(12):2985\u201392.","journal-title":"Rheumatol Int"},{"issue":"12","key":"1482_CR26","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.7314\/APJCP.2012.13.12.6163","volume":"13","author":"HJ Seo","year":"2012","unstructured":"Seo HJ, Oh IH, Yoon SJ. A comparison of the cancer incidence rates between the national cancer registry and insurance claims data in Korea. Asian Pac J Cancer Prev. 2012;13(12):6163\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"44","key":"1482_CR27","first-page":"1434","volume":"59","author":"Centers for Disease C, Prevention","year":"2010","unstructured":"Centers for Disease C, Prevention. Racial\/ethnic disparities and geographic differences in lung cancer incidence\u201438 States and the District of Columbia, 1998-2006. MMWR Morb Mortal Wkly Rep. 2010;59(44):1434\u20138.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"1482_CR28","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10552-005-3635-6","volume":"16","author":"T Haselkorn","year":"2005","unstructured":"Haselkorn T, Whittemore AS, Lilienfeld DE. Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences. Cancer Causes Control. 2005;16(7):781\u20137.","journal-title":"Cancer Causes Control"},{"issue":"9","key":"1482_CR29","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","volume":"56","author":"F Wolfe","year":"2007","unstructured":"Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum. 2007;56(9):2886\u201395.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"1482_CR30","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/14397595.2016.1141740","volume":"26","author":"M Harigai","year":"2016","unstructured":"Harigai M, Nanki T, Koike R, Tanaka M, Watanabe-Imai K, Komano Y, et al. Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide cohort study in Japan. Mod Rheumatol. 2016;26(5):642\u201350.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"1482_CR31","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1093\/ije\/dyp153","volume":"38","author":"JE Ferrie","year":"2009","unstructured":"Ferrie JE, Kivimaki M, Singh-Manoux A, Shortt A, Martikainen P, Head J, et al. Non-response to baseline, non-response to follow-up and mortality in the Whitehall II cohort. Int J Epidemiol. 2009;38(3):831\u20137.","journal-title":"Int J Epidemiol"},{"issue":"6","key":"1482_CR32","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/EDE.0b013e31822939fd","volume":"22","author":"N Greene","year":"2011","unstructured":"Greene N, Greenland S, Olsen J, Nohr EA. Estimating bias from loss to follow-up in the Danish National Birth Cohort. Epidemiology. 2011;22(6):815\u201322.","journal-title":"Epidemiology"},{"issue":"10","key":"1482_CR33","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208105","volume":"75","author":"J Askling","year":"2016","unstructured":"Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, et al. How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. Ann Rheum Dis. 2016;75(10):1789\u201396.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1482_CR34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.semarthrit.2010.08.005","volume":"41","author":"L Carmona","year":"2011","unstructured":"Carmona L, Abasolo L, Descalzo MA, Perez-Zafrilla B, Sellas A, de Abajo F, et al. Cancer in patients with rheumatic diseases exposed to TNF antagonists. Semin Arthritis Rheum. 2011;41(1):71\u201380.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1482_CR35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4143\/crt.2016.089","volume":"48","author":"CM Oh","year":"2016","unstructured":"Oh CM, Won YJ, Jung KW, Kong HJ, Cho H, Lee JK, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2013. Cancer Res Treat. 2016;48(2):436\u201350.","journal-title":"Cancer Res Treat"},{"issue":"19","key":"1482_CR36","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1056\/NEJMp1409841","volume":"371","author":"HS Ahn","year":"2014","unstructured":"Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer \u201cepidemic\u201d\u2014screening and overdiagnosis. N Engl J Med. 2014;371(19):1765\u20137.","journal-title":"N Engl J Med"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-017-1482-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T17:17:58Z","timestamp":1660151878000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-017-1482-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1482"],"URL":"https:\/\/doi.org\/10.1186\/s13075-017-1482-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12]]},"article-number":"277"}}